LOS ANGELES – June 3, 2024 – For the last three decades, breakthroughs have been sparse for soft tissue sarcomas, which are rare cancers that affect muscles, fat and other connective tissues. Today, a ...

Two Complete Metabolic Responses (CMRs) observed in patients with relapsed/refractory metastatic Ewing sarcoma and one Complete Response (CR) ...

CHICAGO and FORT WORTH, Texas, July 17, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on ...

Success rates for drug development in solid tumors remain the lowest of the many therapeutics areas in medicine. Recent advances in drug discovery and development have transformed available therapies ...

CLEVELAND — Childhood cancer is the No. 1 disease-related cause of death among children in the United States, with one in six young patients not surviving. For families grappling with a cancer ...

HOUSTON, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer ...

There has been growing interest in the use of real-world data (RWD) to address clinically and policy-relevant (research) questions that cannot be answered with data from randomized controlled trials ...

Sarcoma treatment at Ohio State helped a teen return to life as a college student, and led her to a new calling as an advocate for patients in her home country of Ecuador. In 2020, Andrea Najas was ...

- Company Initiating Planning of Phase 2 Trial of Elraglusib in Children, Adolescents, and Adults with Refractory/Resistant Ewing Sarcoma CHICAGO and FORT WORTH, Texas, July 17, 2025 (GLOBE NEWSWIRE) ...